What is Kerafast?
Kerafast operates as a specialized provider of rare and unique research reagents, serving as a critical bridge between academic innovation and commercial application. By facilitating the distribution of antibodies, cell culture reagents, and DNA vectors, the company supports high-stakes research in fields such as oncology, immunology, and drug discovery. Their business model is uniquely structured to partner with technology transfer offices and academic institutions, effectively commercializing scientific breakthroughs that might otherwise remain inaccessible to the broader research community. This approach not only streamlines the procurement process for research organizations but also fosters a collaborative ecosystem where scientific contributions are systematically cataloged and made available for global experimentation.
How much funding has Kerafast raised?
Kerafast has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Kerafast
PPP
Public-Private Partnership
What's next for Kerafast?
Following this late-stage funding round, Kerafast is expected to prioritize the scaling of its digital infrastructure and the expansion of its reagent catalog. The strategic deployment of these funds will likely focus on enhancing technical support services and strengthening licensing agreements with research institutions. As the company matures, the focus will shift toward optimizing supply chain logistics to meet the increasing demand for specialized biological tools. By leveraging its established network of academic partners, Kerafast is poised to solidify its role as an essential utility in the biotechnology value chain, potentially exploring new market segments in personalized medicine and advanced therapeutic development.
See full Kerafast company page
